Loading...
The dipeptidyl peptidase IV inhibitors vildagliptin and K-579 inhibit a phospholipase C: a case of promiscuous scaffolds in proteins
The long term side effects of any newly introduced drug is a subject of intense research, and often raging controversies. One such example is the dipeptidyl peptidase-IV (DPP4) inhibitor used for treating type 2 diabetes, which is inconclusively implicated in increased susceptibility to acute pancre...
Na minha lista:
| Udgivet i: | F1000Res |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
F1000Research
2015
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4309170/ https://ncbi.nlm.nih.gov/pubmed/25671081 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12688/f1000research.2-286.v3 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|